Thrombotic thrombocytopenic purpura

3 trials MedDRA PT
3 Registered trials
0 Recruiting
3 Unique sponsors
3 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Monoclonal antibody (angiogenesis) 1 substance
Phase III: 2 Phase I/II: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

2 trials
  • Baxalta Innovations GmbH Commercial
    APADAMTASE ALFA
    2024-513839-24-00 6 countries 2021 n=30 Orphan
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    CAPLACIZUMAB
    2024-513262-19-00 9 countries 2022 n=44 Orphan
    Ended

Phase I/II

1 trial
  • TargED Biopharmaceuticals B.V. Commercial
    UROKINASE, CATALYTIC DOMAIN, FUSED WITH A SINGLE-CHAIN ANTIBODY AGAINST VON WILLEBRAND FACTOR
    2025-523802-34-00 4 countries n=40 Orphan
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Baxalta Innovations GmbH Commercial 1 Phase III 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase III 0
TargED Biopharmaceuticals B.V. Commercial 1 Phase I/II 0
New trials by year
2021
1
2022
1
← All indication landscapes